Premium
Oxcarbazepine Placebo‐Controlled, Dose‐Ranging Trial in Refractory Partial Epilepsy
Author(s) -
Gábor Barcs,
Elizabeth Walker,
Christian E. Elger,
A. Scaramelli,
H. Stefan,
Y. Sturm,
Alan Moore,
G. Flesch,
Lynn D. Kramer,
Joseph D’Souza
Publication year - 2000
Publication title -
epilepsia
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1499-1654.2000.001597.x
Subject(s) - oxcarbazepine , medicine , adverse effect , placebo , partial seizures , refractory (planetary science) , epilepsy , dose ranging study , anesthesia , gastroenterology , double blind , carbamazepine , alternative medicine , physics , pathology , psychiatry , astrobiology
The goal of the study was to evaluate the safety and efficacy of a broad oxcarbazepine (OXC) dosage range (600, 1200, and 2400 mg/d) as adjunctive therapy for uncontrolled partial seizures and to determine the relationship between trough plasma 10-monohydroxy derivative concentrations and OXC safety and efficacy.